Literature DB >> 12600717

Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model.

Jennifer Drake1, Christopher D Link, D Allan Butterfield.   

Abstract

Alzheimer's disease is a progressive, neurodegenerative disorder characterized by senile plaques and neurofibrillary components. Abeta(1-42) is a principal component of senile plaques and is thought to be central to the pathogenesis of the disease. The Alzheimer's disease brain is under significant oxidative stress, and the Abeta(1-42) peptide is known to cause oxidative stress in vitro. One controversy in the amyloid hypothesis is whether or not Abeta plaques are required for toxicity. We have employed a temperature-inducible Abeta expression system in Caenorhabditis elegans to create a strain of worms, CL4176, in which Abeta(1-42) is expressed with a non-permissive temperature of 23 degrees C. The CL4176 strain allows examination of the temporal relationship between Abeta expression, oxidative stress, and Abeta fibril formation. CL4176 were under increased oxidative stress, evidenced by increased protein oxidation indexed by increased carbonyl levels, 24 and 32 h after temperature upshift as compared to the control strain, CL1175. The increased oxidative stress in CL4176 occurred in the absence of Abeta fibril formation, consistent with the notion that the toxic species in Abeta toxicity is pre-fibrillar Abeta and not the Abeta fibril. These results are discussed with reference to Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12600717     DOI: 10.1016/s0197-4580(02)00225-7

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  114 in total

Review 1.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

Review 2.  Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.

Authors:  M Flint Beal
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

3.  Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action.

Authors:  Eugenio Barone; Giovanna Cenini; Fabio Di Domenico; Sarah Martin; Rukhsana Sultana; Cesare Mancuso; Michael Paul Murphy; Elizabeth Head; D Allan Butterfield
Journal:  Pharmacol Res       Date:  2010-12-27       Impact factor: 7.658

4.  Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Aβ accumulation in AD brain.

Authors:  Joshua B Owen; Rukhsana Sultana; Christopher D Aluise; Michelle A Erickson; Tulin O Price; Guojun Bu; William A Banks; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2010-10-07       Impact factor: 7.376

Review 5.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

Review 6.  Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease.

Authors:  D Allan Butterfield; Miranda L Bader Lange; Rukhsana Sultana
Journal:  Biochim Biophys Acta       Date:  2010-02-20

Review 7.  Understanding the molecular basis of Alzheimer's disease using a Caenorhabditis elegans model system.

Authors:  Collin Y Ewald; Chris Li
Journal:  Brain Struct Funct       Date:  2009-12-11       Impact factor: 3.270

8.  Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease.

Authors:  Rukhsana Sultana; William A Banks; D Allan Butterfield
Journal:  J Neurosci Res       Date:  2010-02-15       Impact factor: 4.164

Review 9.  Antioxidants in central nervous system diseases: preclinical promise and translational challenges.

Authors:  Chandrashekhar D Kamat; Sunyana Gadal; Molina Mhatre; Kelly S Williamson; Quentin N Pye; Kenneth Hensley
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

Review 10.  Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment.

Authors:  Rukhsana Sultana; D Allan Butterfield
Journal:  J Bioenerg Biomembr       Date:  2009-10       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.